Tom is a results-oriented executive with more than 25 years of management experience and a globally-recognized authority in university-to-industry technology transfer. He has a record of bringing entrepreneurial thinking, technical skill, and integrity to leadership roles and has made outstanding contributions to the research organizations of major healthcare corporations.
Tom is currently Vice President, Business Development at Global Vaccines, Inc., a not-for-profit company established to translate cutting edge technology into a new generation of vaccines for diseases prevalent among the world's poor. At GVI, his focus is on assuring that the business is a self-sustaining enterprise through a combination of in-licensing, out-licensing and fund raising activities. He also serves as a member of the Board of Directors for Cellatope Corporation, a development stage company focusing on products and services in the autoimmune disease field. Additionally, Tom is the Managing Owner of AuthentiForm Technologies, L.L.C., a start-up stage company licensed to humanitarian uses for a breakthrough authentication technology that enables encoding the formulation of pharmaceutical products.
Previously at Johnson & Johnson, Tom was a Corporate Director in the Corporate Office of Science and Technology, where he developed a model for attracting outside investors to internal J&J technology incubation, and was a consultant to the National Academies of Science's Institute of Medicine Drug Development Forum project to create model technology transfer agreements. Tom was also the global head of the pharmaceutical R&D organization responsible for creating "external R&D" capacity through technology access activities, including managing internal diligence and approval for licenses to new uses for marketed products and support for compound licensing and strategic collaborations.
The foundations to Tom's career were built in product development management. He headed Johnson & Johnson's Ortho Clinical Diagnostics' Immunocytometry business unit in an internal "start-up" that developed reagent, software, and instrument products that grew from $8 million to >$40 million in sales in just 3 years. He was also provided R&D leadership to a management team that proposed and implemented two internal units' merger into a business with combined sales >$200 million. Tom started his industrial career at Becton Dickinson and Company, where he was an inventor of today's most-widely used in the undeveloped world technology for HIV disease monitoring.
Tom earned his PhD in Microbiology & Immunology from the University of North Carolina at Chapel Hill and a BS in Chemistry from Fairfield University, and is also a Registered Patent Agent.
